MARK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4076329	0.52	3/20
SCHEMBL4086090	0.52	3/20
SCHEMBL4088005	0.48	3/20
SCHEMBL4076616	0.48	3/20
SCHEMBL4081430	0.48	3/20
SCHEMBL4081490	0.47	3/20
SCHEMBL4085610	0.47	3/20
SCHEMBL3496512	0.42	3/20
SCHEMBL3495479	0.42	3/20
SCHEMBL3970463	0.73	2/20
SCHEMBL1890595	0.72	2/20
SCHEMBL1781331	0.67	2/20
SCHEMBL3387297	0.65	2/20
SCHEMBL3387284	0.65	2/20
SCHEMBL3389139	0.64	2/20
SCHEMBL344178	0.64	2/20
SCHEMBL3389136	0.64	2/20
SCHEMBL344014	0.63	2/20
SCHEMBL1355087	0.63	2/20
SCHEMBL4213976	0.60	2/20

Clinical trials — most relevant to MARK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI	PHASE2	COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Study of ASTX029 in Subjects With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery	PHASE1	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Integrated Approaches for Identifying Molecular Targets in Liver Disease	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MARK1 binder may also engage these)

Protein	Name	Similarity
O08678	—	1.000	O08678 →
Q05512	—	1.000	Q05512 →
MARK2	Serine/threonine-protein kinase MARK2	1.000	landscape →
Q8VHJ5	—	1.000	Q8VHJ5 →
O08679	—	1.000	O08679 →
MARK3	MAP/microtubule affinity-regulating kinase 3	0.999	landscape →
Q03141	—	0.998	Q03141 →
Q8VHF0	—	0.995	Q8VHF0 →
Q19469	—	0.992	Q19469 →
Q2QMH1	—	0.992	Q2QMH1 →
P06782	—	0.991	P06782 →
PAK3	Serine/threonine-protein kinase PAK 3	0.991	landscape →
A0A1D9QMS2	—	0.991	A0A1D9QMS2 →
P52497	—	0.990	P52497 →
Q8RX66	—	0.989	Q8RX66 →
Q01919	—	0.989	Q01919 →
Q8CIP4	—	0.989	Q8CIP4 →
P40433	—	0.988	P40433 →
O75011	—	0.988	O75011 →
Q9NB31	—	0.988	Q9NB31 →
Q7YQL4	—	0.988	Q7YQL4 →
P12688	—	0.988	P12688 →
P48479	—	0.988	P48479 →
Q7RZD3	—	0.988	Q7RZD3 →
U4PR86	—	0.988	U4PR86 →
Q9LV37	—	0.988	Q9LV37 →
Q9URY1	—	0.988	Q9URY1 →
P24583	—	0.987	P24583 →
Q9HFW2	—	0.987	Q9HFW2 →
O14019	—	0.987	O14019 →